Terms: = Leukemia AND EP300, ENSG00000100393, 2033, RP1-85F18_1, p300
419 results:
1. Discovery of Highly Potent and Efficient CBP/p300 Degraders with Strong
Hu J; Xu H; Wu T; Zhang C; Shen H; Dong R; Hu Q; Xiang Q; Chai S; Luo G; Chen X; Huang Y; Zhao X; Peng C; Wu X; Lin B; Zhang Y; Xu Y
J Med Chem; 2024 May; 67(9):6952-6986. PubMed ID: 38649304
[TBL] [Abstract] [Full Text] [Related]
2. ep300-ZNF384 transactivates IL3RA to promote the progression of B-cell acute lymphoblastic leukemia.
Hou Z; Ren Y; Zhang X; Huang D; Yan F; Sun W; Zhang W; Zhang Q; Fu X; Lang Z; Chu C; Zou B; Gao B; Jin B; Kang Z; Liu Q; Yan J
Cell Commun Signal; 2024 Apr; 22(1):211. PubMed ID: 38566191
[TBL] [Abstract] [Full Text] [Related]
3. Transcription Factor MYB as Therapeutic Target: Current Developments.
Klempnauer KH
Int J Mol Sci; 2024 Mar; 25(6):. PubMed ID: 38542205
[TBL] [Abstract] [Full Text] [Related]
4. DNA Copy Number Alterations and Copy Neutral Loss of Heterozygosity in Adult Ph-Negative Acute B-Lymphoblastic leukemia: Focus on the Genes Involved.
Risinskaya N; Gladysheva M; Abdulpatakhov A; Chabaeva Y; Surimova V; Aleshina O; Yushkova A; Dubova O; Kapranov N; Galtseva I; Kulikov S; Obukhova T; Sudarikov A; Parovichnikova E
Int J Mol Sci; 2023 Dec; 24(24):. PubMed ID: 38139431
[TBL] [Abstract] [Full Text] [Related]
5. Inhibition of CREB Binding and Function with a Dual-Targeting Ligand.
Liu Y; Joy ST; Henley MJ; Croskey A; Yates JA; Merajver SD; Mapp AK
Biochemistry; 2024 Jan; 63(1):1-8. PubMed ID: 38086054
[TBL] [Abstract] [Full Text] [Related]
6. Synergistic cytotoxicity of decitabine and YM155 in leukemia cells through upregulation of SLC35F2 and suppression of MCL1 and survivin expression.
Chiou JT; Chang LS
Apoptosis; 2024 Apr; 29(3-4):503-520. PubMed ID: 38066391
[TBL] [Abstract] [Full Text] [Related]
7. Therapeutic targeting of ep300/CBP by bromodomain inhibition in hematologic malignancies.
Nicosia L; Spencer GJ; Brooks N; Amaral FMR; Basma NJ; Chadwick JA; Revell B; Wingelhofer B; Maiques-Diaz A; Sinclair O; Camera F; Ciceri F; Wiseman DH; Pegg N; West W; Knurowski T; Frese K; Clegg K; Campbell VL; Cavet J; Copland M; Searle E; Somervaille TCP
Cancer Cell; 2023 Dec; 41(12):2136-2153.e13. PubMed ID: 37995682
[TBL] [Abstract] [Full Text] [Related]
8. Hydroquinone-selected chronic myelogenous leukemia cells are sensitive to chloroquine-induced cytotoxicity via MCL1 suppression and glycolysis inhibition.
Chiou JT; Lee YC; Chang LS
Biochem Pharmacol; 2023 Dec; 218():115934. PubMed ID: 37989415
[TBL] [Abstract] [Full Text] [Related]
9. DUX4-r exerts a neomorphic activity that depends on GTF2I in acute lymphoblastic leukemia.
Campolungo D; Salomé M; Biferali B; Tascini AS; Gabellini D
Sci Adv; 2023 Sep; 9(37):eadi3771. PubMed ID: 37713484
[TBL] [Abstract] [Full Text] [Related]
10. YAP suppresses human T-cell leukemia virus type 1 transcription.
Li H; Zou F; Zhang J; Zhu S; Chu K; Zhang X; Zhao T
J Med Virol; 2023 Sep; 95(9):e29065. PubMed ID: 37661566
[TBL] [Abstract] [Full Text] [Related]
11. [Clinical characteristics and outcomes of childhood B-ALL with ZNF384 and MEF2D rearrangements].
Hirabayashi S; Manabe A; Ohki K; Kiyokawa N
Rinsho Ketsueki; 2023; 64(7):633-638. PubMed ID: 37544723
[TBL] [Abstract] [Full Text] [Related]
12. KAT6A::ep300 fusion in congenital myeloid sarcoma: Yet another novel molecular marker indicating spontaneous remission?: A case report.
Hosahalli Vasanna S; Shah SD; Rohr BR; Roche B; Meyerson H; Pateva I
Medicine (Baltimore); 2023 Jul; 102(30):e34258. PubMed ID: 37505185
[TBL] [Abstract] [Full Text] [Related]
13. NPM1 mutation reprograms leukemic transcription network via reshaping TAD topology.
Lai Q; Hamamoto K; Luo H; Zaroogian Z; Zhou C; Lesperance J; Zha J; Qiu Y; Guryanova OA; Huang S; Xu B
Leukemia; 2023 Aug; 37(8):1732-1736. PubMed ID: 37365294
[TBL] [Abstract] [Full Text] [Related]
14. ZNF384-Related Fusion Genes in Acute Lymphoblastic leukemia.
Zhu L; Bai W; Cheng Q; Fang J
Cancer Control; 2023; 30():10732748231182787. PubMed ID: 37306722
[TBL] [Abstract] [Full Text] [Related]
15. Discovery of Exceptionally Potent, Selective, and Efficacious PROTAC Degraders of CBP and p300 Proteins.
Thomas JE; Wang M; Jiang W; Wang M; Wang L; Wen B; Sun D; Wang S
J Med Chem; 2023 Jun; 66(12):8178-8199. PubMed ID: 37276143
[TBL] [Abstract] [Full Text] [Related]
16. LKB1 controls inflammatory potential through CRTC2-dependent histone acetylation.
Compton SE; Kitchen-Goosen SM; DeCamp LM; Lau KH; Mabvakure B; Vos M; Williams KS; Wong KK; Shi X; Rothbart SB; Krawczyk CM; Jones RG
Mol Cell; 2023 Jun; 83(11):1872-1886.e5. PubMed ID: 37172591
[TBL] [Abstract] [Full Text] [Related]
17. Efficient diagnosis of hematologic malignancies using bone marrow microscopic images: A method based on MultiPathGAN and MobileViTv2.
Yang G; Qin Z; Mu J; Mao H; Mao H; Han M
Comput Methods Programs Biomed; 2023 Jul; 237():107583. PubMed ID: 37167882
[TBL] [Abstract] [Full Text] [Related]
18. A novel lncRNA SNHG29 regulates ep300- related histone acetylation modification and inhibits FLT3-ITD AML development.
Liu S; Zhou J; Ye X; Chen D; Chen W; Lin Y; Chen Z; Chen B; Shang J
Leukemia; 2023 Jul; 37(7):1421-1434. PubMed ID: 37157016
[TBL] [Abstract] [Full Text] [Related]
19. Elderly people with human T-cell leukemia virus type 1-associated myelopathy present an early impairment in cognitive skills.
Sousa BRM; Labanca L; Diniz ML; Rausse NCB; Gonçalves DU
Arq Neuropsiquiatr; 2023 Mar; 81(3):253-262. PubMed ID: 37059435
[TBL] [Abstract] [Full Text] [Related]
20. Targeting of epigenetic co-dependencies enhances anti-AML efficacy of Menin inhibitor in AML with MLL1-r or mutant NPM1.
Fiskus W; Mill CP; Birdwell C; Davis JA; Das K; Boettcher S; Kadia TM; DiNardo CD; Takahashi K; Loghavi S; Soth MJ; Heffernan T; McGeehan GM; Ruan X; Su X; Vakoc CR; Daver N; Bhalla KN
Blood Cancer J; 2023 Apr; 13(1):53. PubMed ID: 37055414
[TBL] [Abstract] [Full Text] [Related]
[Next]
